The European Medicines Agency has okayed Trimbow, an inhaled combination of three drugs to treat COPD flare-ups in some patients.

Trimbow (beclometasone dipropionate/formoterol fumarate dihydrate/glycopyrronium bromide) is an inhaled formulation containing a glucocorticoid, a long-acting ?2 receptor agonist, and a long-acting muscarinic antagonist, respectively.

Beclometasone reduces lung inflammation, whereas formoterol and glycopyrronium relax bronchial smooth muscle and dilate the airways.

The triple-drug combination will be formulated as a pressurized metered-dose inhaler that administers a solution with a nominal dose per actuation of 87 ?g/5 ?g/9 ?g of the active substances, respectively.

The inhaled combination relieves and prevents symptoms, including shortness of breath, wheezing, and cough, and reduces flare-ups of COPD symptoms. The most frequent adverse events are oral candidiasis, muscle spasm, and dry mouth.